The evaluation of pupil diameter by using Sirius before and after phacoemulsification in healthy, diabetic and hypertension patients

Abstract

Background: Pupil size can affect the selection of the ablation region in refractive surgery and intraocular lens design in cataract surgery. Therefore, the evaluation of pupil diameter (PD), one of the anterior segment parameters, is an important component of ophthalmological examination. Material and methods: Seventy-one healthy patients, 64 patients with Systemic Hypertension (HT), and 65 patients with Diabetes Mellitus (DM) scheduled for phacoemulsification were included in the study. PD was measured before and one month after surgery using combined Scheimpflug-Placido disk topography (Sirius, CSO Inc.). Preoperative PD values of the groups were compared. The PD of the groups was compared in the 1st month after surgery. Then, preoperative and postoperative pupil diameter values of the groups were compared. The effect of the surgery on the change in pupil diameter (effect value) in the groups was also examined. Results: Pre- and postoperative PD only differed significantly between the healthy and DM groups (P = .039 and P = .045, respectively). PD decreased in all three groups after phacoemulsification. Pre-and postoperative PD differed significantly in the healthy group (4.78 ± 0.94 and 3.01 ± 0.48 mm, respectively, P < .05). Pre- and postoperative PD values also differed significantly (4.69 ± 0.84 and 2.95 ± 0.42 mm, respectively, P < .05). In the DM group, Pre- and postoperative PD also differed significantly in the DM group (4.38 ± 1.08 and 2.82 ± 0.43 mm, respectively, P < .05). The effect values of PD changes differed in the healthy, DM, and HT groups (1.95, 1.41, and 2.28, respectively). Phacoemulsification was observed to have a greater effect on PD change in HT patients. Conclusions: PD was smaller in DM patients than in the other groups. PD decreased in all three groups after phacoemulsification. This change should be remembered when planning cataract surgery for chronic metabolic patients.